Using Blood and Saliva mRNA to Detect Breast Cancer
This patent describes a method using specific messenger RNA (mRNA) levels in blood or saliva to help detect breast cancer or determine its prognosis.
Patent Number
US 20240117444
Status
Active
Filing Date
February 11, 2022
Grant Date
—
Expiration
February 11, 2042
Claims
53
Assignee
Mammogen
Inventors
Patrick Lilley, Martin J. Keiser, III
Citations
1 forward · 0 backward
What it covers
This patent outlines a method for detecting breast cancer or predicting its outcome. It involves measuring the levels of at least one specific type of molecule called messenger RNA (mRNA) in a sample from a person, like blood or saliva. These measured levels are then sent to a computer and compared to a baseline level from a healthy sample. If the mRNA levels are different, it can indicate the presence of breast cancer or help doctors understand how aggressive it might be. The patent lists 26 specific mRNAs that can be used, and suggests using a combination of them to create a 'biomarker fingerprint' for more accurate diagnosis or prognosis. It also mentions using this information to guide treatment decisions and distinguish between different stages of the cancer.
What it doesn't cover
- —Detecting breast cancer using only imaging techniques like mammograms.
- —Diagnosing breast cancer based on physical examination alone.
- —Using protein levels or DNA mutations as the primary diagnostic markers.
- —Methods that do not involve measuring mRNA expression levels.
- —Detecting cancers other than breast cancer.
The clever bit
The innovation lies in identifying and utilizing a specific panel of 26 mRNA molecules whose expression levels in blood or saliva are significantly altered in the presence of breast cancer, creating a unique 'fingerprint' for diagnosis and prognosis.
Why it matters
Early and accurate detection of breast cancer significantly improves treatment outcomes and patient survival rates. This patent offers a potential non-invasive method, using readily available samples like blood or saliva, to identify the disease or its likely progression. This could lead to earlier intervention and more personalized treatment strategies.
Real-world examples
- 1.Mammogen Inc.'s diagnostic tests
- 2.Blood-based cancer screening technologies
- 3.Saliva-based diagnostic assays
Generated by PatentBrief · Not legal advice · patentbrief.org
US 20240117444 · 2026